Global Psoriasis Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Psoriasis Treatment Market Segmentation, By Drug Class (Corticosteroids, TNF Inhibitors, Interleukins, and Others), Type (Plaque Psoriasis, Psoriatic Arthritis, and Others), Route of Administration (Oral, Parenteral, and Topical), Application (Topical Therapeutic Drugs, Systemic Therapeutic Drugs, and Combinations), End User (Hospital Pharmacy, Clinics, Retail Pharmacies, and Online Sales)- Industry Trends and Forecast to 2033

Psoriasis Treatment Market Size

• The global psoriasis treatment market size was valued at USD 29.20 billion in 2025 and is expected to reach USD 53.44 billion by 2033, at a CAGR of 7.85% during the forecast period
• The market growth is largely fueled by the growing prevalence of psoriasis worldwide, rising awareness of treatment options, and rapid adoption of advanced biologic and targeted therapies that offer improved efficacy and safety profiles
• Furthermore, increasing diagnosis rates, expanding R&D investments, and consumer demand for personalized and effective treatment solutions are establishing innovative therapeutic options as the preferred management strategy for patients. These converging factors are accelerating uptake of psoriasis treatment solutions, thereby significantly boosting the industry’s growth

Psoriasis Treatment Market Analysis

• Psoriasis treatments, encompassing corticosteroids, TNF inhibitors, interleukins, and other drug classes, are increasingly vital components of modern dermatological care due to their effectiveness in managing chronic symptoms, improving patient quality of life, and preventing disease progression
• The escalating demand for psoriasis treatments is primarily fueled by the rising prevalence of plaque psoriasis and psoriatic arthritis globally, growing awareness of available therapies, and an increasing preference for advanced systemic and combination treatment options that offer improved efficacy and safety
• North America dominated the psoriasis treatment market with the largest revenue share of 38.5% in 2025, characterized by high healthcare spending, early adoption of parenteral biologic therapies, and a strong presence of leading pharmaceutical companies, with the U.S. experiencing substantial growth in treatment uptake driven by innovations in interleukin-targeting agents
• Asia-Pacific is expected to be the fastest growing region in the psoriasis treatment market during the forecast period due to increasing healthcare access, rising disposable incomes, and expanding distribution through hospitals, clinics, retail pharmacies, and online sales channels
• Parenteral segment dominated the market with a market share of 46.7% in 2025, driven by the high adoption of injectable biologics that provide superior disease control and long-term treatment outcomes compared to traditional oral and topical therapies

Report Scope and Psoriasis Treatment Market Segmentation

Psoriasis Treatment Market Trends

“Shift Towards Biologics and Targeted Therapies”

• A significant and accelerating trend in the global psoriasis treatment market is the growing adoption of biologics and targeted therapies, which provide improved efficacy, fewer side effects, and long-term disease control for moderate-to-severe psoriasis patients
• For instance, Cosentyx (secukinumab) has shown high efficacy in treating plaque psoriasis and psoriatic arthritis, gaining widespread physician preference and patient acceptance across multiple regions
• Targeted therapies enable precise modulation of the immune system, such as interleukin inhibitors reducing inflammation while minimizing systemic exposure, thereby offering safer treatment options
• The integration of biologics with personalized treatment plans based on genetic profiling and disease severity allows dermatologists to optimize therapeutic outcomes and minimize trial-and-error approaches
• This trend towards more advanced, precise, and patient-specific therapies is fundamentally reshaping treatment expectations, with companies such as AbbVie and Novartis launching newer interleukin-targeting biologics to address unmet patient needs
• The demand for effective, long-lasting, and safer therapies is growing rapidly across both hospital and outpatient settings, as patients increasingly prioritize quality of life and sustained disease management
• Rising interest in combination therapies, which integrate biologics with topical or systemic drugs, is offering dermatologists flexible treatment options to manage refractory or complex psoriasis cases

Psoriasis Treatment Market Dynamics

Driver

“Rising Prevalence and Increasing Awareness of Psoriasis”

• The increasing prevalence of psoriasis worldwide, coupled with growing patient and physician awareness of advanced treatment options, is a significant driver for heightened demand in the market
• For instance, in 2025, AbbVie expanded its global distribution of Skyrizi (risankizumab) to address rising moderate-to-severe plaque psoriasis cases, highlighting the role of biologics in driving market growth
• As more patients are diagnosed and seek treatment, systemic and biologic therapies offer superior disease control compared to traditional topical treatments, providing a compelling option for dermatologists and patients
• Furthermore, increasing access to healthcare services, awareness campaigns, and patient support programs are making advanced therapies more widely accepted and adopted globally
• The convenience of self-administered injectable therapies, combined with improved patient adherence and efficacy monitoring through clinics and telemedicine, is key to market expansion
• Government initiatives and health insurance coverage improvements in major markets are facilitating patient access to expensive biologic therapies, further driving adoption rates
• Rising research and development investments by pharmaceutical companies are continuously introducing new therapies, expanding treatment portfolios, and creating additional growth opportunities
• Collaborations between dermatology centers, hospitals, and patient advocacy groups are increasing awareness and early diagnosis, which in turn boosts demand for effective treatments

Restraint/Challenge

“High Treatment Costs and Limited Accessibility”

• The high cost of biologics and advanced systemic therapies, coupled with insurance coverage limitations, poses a significant challenge to broader market penetration, particularly in developing regions
• For instance, many patients in low- and middle-income countries are unable to access interleukin inhibitors due to prohibitive costs, limiting treatment adoption despite high efficacy
• Addressing affordability through patient assistance programs, biosimilar launches, and government healthcare initiatives is crucial for improving accessibility and expanding the patient base
• In addition, treatment side effects, such as increased risk of infections with immunosuppressive therapies, create patient hesitancy and require careful monitoring by healthcare providers
• While advances in treatment options are increasing, the combination of cost barriers and safety concerns can hinder widespread adoption and market growth
• Overcoming these challenges through improved insurance coverage, development of cost-effective biosimilars, and patient education on safety management will be vital for sustained market expansion
• Limited infrastructure for cold-chain storage and delivery of biologics in certain regions can restrict availability, further challenging market penetration
• Stringent regulatory approvals and variations in drug reimbursement policies across countries can delay launch of new therapies, affecting market growth momentum

Psoriasis Treatment Market Scope

The market is segmented on the basis of drug class, type, route of administration, application, and end user.

•  By Drug Class

On the basis of drug class, the psoriasis treatment market is segmented into corticosteroids, TNF inhibitors, interleukins, and others. The interleukins segment dominated the market with the largest revenue share of 45% in 2025, driven by their targeted action against specific inflammatory pathways, resulting in higher efficacy and fewer systemic side effects. Interleukin inhibitors are widely prescribed for moderate-to-severe plaque psoriasis and psoriatic arthritis, offering sustained disease control. Physicians often favor interleukins for patients who do not respond to traditional therapies or TNF inhibitors. The segment’s growth is also supported by increasing approvals of newer interleukin-targeting biologics by regulatory authorities. Patient adherence is enhanced due to convenient dosing schedules, such as monthly or bi-monthly injections. The combination of clinical efficacy, patient convenience, and strong physician adoption makes interleukins the largest revenue-generating drug class in the market.

The TNF inhibitors segment is expected to witness the fastest growth rate of 12.8% CAGR from 2026 to 2033, fueled by rising adoption in emerging markets and expansion of insurance coverage. TNF inhibitors are effective for both psoriasis and psoriatic arthritis, increasing their utility in multi-symptom management. Growing awareness among patients and dermatologists about early intervention benefits is boosting TNF inhibitor uptake. Biosimilar launches are improving affordability, further expanding market access. The segment benefits from established clinical data supporting long-term safety and efficacy, encouraging both physicians and patients to prefer TNF inhibitors. Increasing R&D investments by key pharmaceutical companies are expected to introduce next-generation TNF inhibitors, further propelling growth.

• By Type

On the basis of type, the psoriasis treatment market is segmented into plaque psoriasis, psoriatic arthritis, and others. The plaque psoriasis segment dominated the market with a revenue share of 58% in 2025, as it represents the most common manifestation of the disease affecting a majority of patients. Treatments for plaque psoriasis include topical therapies, systemic drugs, and biologics, making it a major contributor to overall market revenue. Dermatologists prefer targeted therapies for moderate-to-severe plaque psoriasis due to higher efficacy and improved patient adherence. Patient awareness campaigns and early diagnosis programs have also increased the treatment rate for plaque psoriasis. The chronic nature of the disease requires long-term therapy, sustaining recurring demand. Pharmaceutical companies are continuously innovating formulations to improve convenience and outcomes, further supporting market dominance.

The psoriatic arthritis segment is expected to witness the fastest CAGR of 11.5% from 2026 to 2033, driven by rising diagnosis rates and increasing adoption of systemic and biologic therapies. Psoriatic arthritis can cause joint damage if untreated, prompting higher physician intervention. Awareness among patients about the benefits of early treatment is growing, especially in developed markets. Combination therapies targeting both skin and joint symptoms are gaining traction, boosting treatment uptake. Market growth is further supported by increasing access to specialty care clinics and insurance coverage for biologics. Pharmaceutical innovations focusing on dual-action therapies for skin and joint manifestations enhance the segment’s growth potential.

• By Route of Administration

On the basis of route of administration, the market is segmented into oral, parenteral, and topical. The parenteral segment dominated the market with a share of 46.7% in 2025, driven by the high adoption of injectable biologics and interleukin inhibitors that provide superior disease control. Parenteral therapies are often preferred for moderate-to-severe cases and for patients unresponsive to oral or topical treatments. Injections offer controlled dosing and longer intervals between administrations, improving patient adherence. Clinics and hospitals widely administer parenteral therapies due to monitoring requirements. Biologics delivered parenterally are supported by clinical evidence demonstrating long-term efficacy and safety. The growth is further aided by patient preference for less frequent dosing and better management of chronic symptoms.

The oral segment is expected to witness the fastest CAGR of 10.9% from 2026 to 2033, fueled by the convenience of pill-based administration and the increasing availability of small-molecule therapies. Oral treatments are easier for patients to self-administer, enhancing adherence. New oral therapies targeting specific inflammatory pathways are being approved, increasing clinical adoption. Patients with mild-to-moderate psoriasis prefer oral drugs due to convenience and lower invasiveness compared to injections. Rising awareness among dermatologists about oral treatment efficacy is driving prescription rates. Emerging markets are increasingly adopting oral therapies due to improved affordability and distribution access.

• By Application

On the basis of application, the market is segmented into topical therapeutic drugs, systemic therapeutic drugs, and combinations. The systemic therapeutic drugs segment dominated the market with a revenue share of 52% in 2025, driven by the high prevalence of moderate-to-severe psoriasis cases requiring systemic intervention. Systemic drugs, including biologics and oral therapies, offer comprehensive disease management and improved long-term outcomes. Physicians prefer systemic therapies for patients with extensive lesions or joint involvement. Recurrent usage and continuous monitoring contribute to sustained revenue generation. Increased insurance coverage and patient awareness programs have accelerated systemic therapy adoption. Pharmaceutical companies are focusing on next-generation systemic therapies with enhanced safety profiles, reinforcing market leadership.

The combination therapies segment is expected to witness the fastest CAGR of 13.2% from 2026 to 2033, fueled by the need to manage complex cases using multi-mechanism approaches. Combination therapy integrates topical, systemic, and biologic treatments to maximize efficacy. Patients with refractory or severe psoriasis benefit from tailored combination regimens. Rising research on synergistic effects of combination therapies is boosting physician confidence. Healthcare providers are increasingly adopting combination approaches to reduce relapse rates and improve patient quality of life. The growing prevalence of difficult-to-treat cases is supporting the adoption of combination therapy globally.

• By End User

On the basis of end user, the market is segmented into hospital pharmacy, clinics, retail pharmacies, and online sales. The hospital pharmacy segment dominated the market with a revenue share of 41% in 2025, driven by the administration of biologics, systemic therapies, and parenteral drugs under professional supervision. Hospitals offer treatment monitoring, patient education, and adherence programs, which are critical for chronic management. Specialist dermatology centers within hospitals provide access to advanced therapies and early diagnosis. Hospital pharmacies benefit from recurring prescriptions and institutional procurement contracts, supporting revenue growth. Insurance reimbursements and hospital partnerships enhance affordability and access. Hospitals remain the preferred channel for moderate-to-severe cases, reinforcing dominance.

The online sales segment is expected to witness the fastest CAGR of 15.5% from 2026 to 2033, fueled by increasing e-pharmacy adoption, convenience, and home delivery services. Online platforms allow patients to access medications discreetly, including prescription fulfillment for oral and topical drugs. Telemedicine integration is further driving online pharmacy growth. Online sales improve access in remote or underserved regions, enhancing patient compliance. E-commerce discounts and subscription models attract cost-sensitive patients. Rising digital literacy and smartphone penetration accelerate market expansion through online channels.

Psoriasis Treatment Market Regional Analysis

• North America dominated the psoriasis treatment market with the largest revenue share of 38.5% in 2025, characterized by high healthcare spending, early adoption of parenteral biologic therapies, and a strong presence of leading pharmaceutical companies
• Patients and healthcare providers in the region prioritize effective, long-term treatment options such as interleukin inhibitors and TNF inhibitors, supported by strong clinical evidence and established treatment guidelines
• This widespread adoption is further supported by well-developed healthcare infrastructure, high awareness of psoriasis management options, insurance coverage for expensive therapies, and access to specialty dermatology clinics, establishing biologics and systemic therapies as the preferred treatment solutions for moderate-to-severe cases in both hospital and outpatient settings

U.S. Psoriasis Treatment Market Insight

The U.S. psoriasis treatment market captured the largest revenue share of 82% in 2025 within North America, fueled by the rising prevalence of moderate-to-severe psoriasis and the widespread adoption of biologics and targeted therapies. Patients and healthcare providers increasingly prioritize long-term disease management with interleukin and TNF inhibitor therapies. The growing preference for early diagnosis and personalized treatment plans, combined with robust insurance coverage and specialty dermatology clinics, further propels the market. Moreover, patient awareness programs and R&D investments by key pharmaceutical companies are significantly contributing to market expansion.

Europe Psoriasis Treatment Market Insight

The Europe psoriasis treatment market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing awareness of advanced treatment options and stringent healthcare regulations. The rise in urbanization and demand for effective management of chronic conditions is fostering the adoption of biologics and systemic therapies. European patients and physicians are drawn to personalized, guideline-based therapies that offer higher efficacy and fewer side effects. The region is experiencing significant growth across hospital, clinic, and retail pharmacy channels, with biologics being increasingly incorporated into treatment regimens for both new and established patients.

U.K. Psoriasis Treatment Market Insight

The U.K. psoriasis treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by rising patient awareness, high adoption of biologics, and strong healthcare infrastructure. In addition, early diagnosis initiatives and concerns regarding disease progression are encouraging both patients and healthcare providers to choose advanced systemic therapies. The U.K.’s robust insurance coverage, coupled with widespread access to dermatology specialists and e-pharmacies, is expected to continue stimulating market growth. The preference for combination therapies to manage refractory cases further supports the expansion of the market.

Germany Psoriasis Treatment Market Insight

The Germany psoriasis treatment market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of personalized therapies and strong healthcare support systems. Germany’s well-developed infrastructure, emphasis on clinical research, and focus on patient-centric care promote the adoption of biologics and systemic treatments. The integration of teledermatology services and specialty clinics is also becoming increasingly prevalent, with patients showing a strong preference for advanced therapies offering long-term disease control and safety. Innovative treatment access programs further enhance adoption in both hospital and outpatient settings.

Asia-Pacific Psoriasis Treatment Market Insight

The Asia-Pacific psoriasis treatment market is poised to grow at the fastest CAGR of 23% during the forecast period of 2026 to 2033, driven by rising prevalence, growing healthcare awareness, and improving access to advanced therapies in countries such as China, Japan, and India. The region's increasing adoption of biologics, government healthcare initiatives, and expanding healthcare infrastructure are driving market growth. Furthermore, the availability of cost-effective biosimilars and systemic therapies is expanding treatment access to a wider patient population. Rising patient awareness and specialty dermatology centers are also fueling adoption in both hospital and clinic settings.

Japan Psoriasis Treatment Market Insight

The Japan psoriasis treatment market is gaining momentum due to the country’s high awareness of biologics, strong healthcare infrastructure, and focus on patient quality of life. Adoption of advanced therapies is driven by rising moderate-to-severe psoriasis cases and the growing integration of teledermatology and clinic-based monitoring. The aging population is likely to increase demand for convenient, effective treatment options. Furthermore, Japan’s emphasis on early diagnosis, preventive care, and personalized therapies is fueling market expansion across hospital and outpatient channels.

India Psoriasis Treatment Market Insight

The India psoriasis treatment market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to rising prevalence, growing healthcare access, and increasing adoption of biologics and systemic therapies. India has a large patient base for psoriasis, and awareness programs are improving early diagnosis rates. The push towards digital health initiatives, affordable biosimilars, and expanding specialty dermatology clinics are key factors propelling the market. In addition, increasing urbanization, rising disposable incomes, and insurance coverage improvements are enhancing treatment affordability and adoption across hospital, clinic, and retail pharmacy channels.

Psoriasis Treatment Market Share

The Psoriasis Treatment industry is primarily led by well-established companies, including:

• AbbVie Inc (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Biogen Inc. (U.S.)
• Sanofi (France)
• Merck & Co., Inc., (U.S.)
• Bristol‑Myers Squibb Company, (U.S.)
• Celgene Corporation (U.S.)
• Sun Pharmaceutical Industries Ltd., (India)
• Teva Pharmaceutical Industries Ltd., (Israel)
• Alvotech hf. (Iceland)
• Protagonist Therapeutics, Inc., (U.S.)
• Roivant Sciences Ltd., (U.S.)
• Organon & Co., (U.S.)
• Stiefel Laboratories, Inc. (U.S.)
• Horizon Therapeutics plc (Ireland)

What are the Recent Developments in Global Psoriasis Treatment Market?

• In December 2025, Takeda revealed that its AI‑designed experimental oral drug zasocitinib achieved significantly clearer skin outcomes in two late‑stage trials for plaque psoriasis, positioning it as a strong potential competitor to existing oral and injectable therapies pending regulatory filings
• In September 2025, the U.S. FDA approved TREMFYA® (guselkumab) for pediatric patients aged six and older with moderate‑to‑severe plaque psoriasis and active psoriatic arthritis, becoming the first IL‑23 inhibitor with this expanded indication and offering new treatment options for younger patients
• In October 2023, the U.S. Food and Drug Administration approved BIMZELX® (bimekizumab‑bkzx), the first biologic specifically designed to inhibit both IL‑17A and IL‑17F, for the treatment of adults with moderate‑to‑severe plaque psoriasis, marking a significant advancement in targeted immunotherapy for the disease
• In October 2023, the U.S. FDA approved Amgen’s biosimilar version of Johnson & Johnson’s Stelara (ustekinumab), expanding access to a lower‑cost biologic option for plaque psoriasis and related inflammatory conditions, a move expected to influence pricing and accessibility
• In September 2022, the U.S. FDA approved Sotyktu™ (deucravacitinib), the first oral TYK2 inhibitor for moderate‑to‑severe plaque psoriasis, representing a major shift toward effective oral treatment alternatives alongside injectable biologics

SKU-26330